• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.

作者信息

De Vuyst Richard C, Bennard Erin, Kam Charissa W, McKinzie Cameron J, Esther Charles R

机构信息

Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.

出版信息

Pediatr Pulmonol. 2023 May;58(5):1592-1594. doi: 10.1002/ppul.26334. Epub 2023 Feb 13.

DOI:10.1002/ppul.26334
PMID:36718851
Abstract
摘要

相似文献

1
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托治疗可减轻囊性纤维化患者的气道炎症。
Pediatr Pulmonol. 2023 May;58(5):1592-1594. doi: 10.1002/ppul.26334. Epub 2023 Feb 13.
2
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
3
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.适合调节剂药物的患者：来自土耳其囊性纤维化登记处的数据。
Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.
4
Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.一名患有囊性纤维化的青春期女性过量服用依列卡福妥-替扎卡福妥-依伐卡福。
Pediatr Pulmonol. 2022 Dec;57(12):3174-3176. doi: 10.1002/ppul.26116. Epub 2022 Aug 24.
5
Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.针对年龄在6至11岁、患有囊性纤维化、至少有一个F508DEL等位基因且患有晚期肺部疾病的儿童使用依列卡福妥/替扎卡福妥/依伐卡托：一项为期24周的观察性研究。
Pediatr Pulmonol. 2022 Sep;57(9):2253-2256. doi: 10.1002/ppul.25980. Epub 2022 May 25.
6
Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对成年囊性纤维化患者N1303K变异体的有效性
Arch Bronconeumol. 2024 Aug;60(8):526-528. doi: 10.1016/j.arbres.2024.04.007. Epub 2024 Apr 24.
7
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
8
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.依列卡福妥/替扎卡福妥/依伐卡托对一名携带A559T和3120+1G>CFTR变异的男性的临床疗效。
Pediatr Pulmonol. 2024 Jul;59(7):2009-2011. doi: 10.1002/ppul.26997. Epub 2024 Apr 12.
9
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
10
Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?囊性纤维化：避免碾碎依列卡福/替扎卡福/依伐卡托（ETI）片剂重要吗？
Pediatr Pulmonol. 2023 Dec;58(12):3603-3604. doi: 10.1002/ppul.26682. Epub 2023 Sep 13.

引用本文的文献

1
Deleterious effect of on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.依列卡福妥/替扎卡福妥/依伐卡托对F508del-CFTR的挽救作用在患者来源的鼻细胞中存在临床菌株依赖性。
ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00970-2024. eCollection 2025 May.
2
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators.高效CFTR调节剂时代囊性纤维化个性化医疗的进展
Mol Cell Pediatr. 2025 May 5;12(1):6. doi: 10.1186/s40348-025-00194-0.
3
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.
依列卡福妥/替扎卡福妥/依伐卡托与囊性纤维化儿童及青少年的炎症：一项回顾性双中心队列研究
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251314706. doi: 10.1177/17534666251314706.
4
CCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice.CCR2+单核细胞对于野生型和囊性纤维化小鼠清除急性肺部铜绿假单胞菌感染并非必需。
J Leukoc Biol. 2025 Mar 14;117(3). doi: 10.1093/jleuko/qiae218.
5
Cystic fibrosis year in review 2023.囊性纤维化 2023 年年鉴
Pediatr Pulmonol. 2024 Dec;59(12):3106-3116. doi: 10.1002/ppul.27190. Epub 2024 Jul 26.
6
Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del.依伐卡托/泰它卡托/艾美卡替三联复方干糖浆治疗 F508del 杂合子成人囊性纤维化的抗炎作用。
PLoS One. 2024 May 31;19(5):e0304555. doi: 10.1371/journal.pone.0304555. eCollection 2024.
7
Raman Spectroscopy and Cystic Fibrosis Disease: An Alternative Potential Tool for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Response Differentiation-A Pilot Study Based on Serum Samples.拉曼光谱与囊性纤维化疾病：囊性纤维化跨膜电导调节因子（CFTR）调节剂反应差异的另一种潜在工具——基于血清样本的初步研究
Molecules. 2024 Jan 16;29(2):433. doi: 10.3390/molecules29020433.
8
Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis.预测囊性纤维化中CFTR调节剂治疗效果及监测疾病严重程度的实验室工具
J Pers Med. 2024 Jan 13;14(1):93. doi: 10.3390/jpm14010093.
9
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.CFTR调节剂依列卡福-替扎卡福-依伐卡福的批准后研究。
Front Pharmacol. 2023 Mar 21;14:1158207. doi: 10.3389/fphar.2023.1158207. eCollection 2023.